文献速递妇科

子宫内膜癌队列中的HER2表达

HER2 expression in an endometrial cancer cohort.
PubMed 文献 · Gynecol Oncol · 2025-08-05

这项回顾性单机构研究纳入249例新诊断子宫内膜癌患者,其中220例肿瘤进行了HER2免疫组化检测,131例(59.5%)HER2表达,67例(30.5%)为2+或3+。HER2表达肿瘤更常见于晚期、非子宫内膜样组织学及p53异常。

要点

  • 新诊断子宫内膜癌中59.5%HER2表达,30.5%为2+或3+。
  • HER2表达肿瘤更常见于晚期、非子宫内膜样及p53异常。
  • HER2表达分布于所有组织学和分子亚型,作者认为所有子宫内膜肿瘤应行HER2免疫组化检测。

核心结论

  • 本回顾性研究中,60%的新诊断子宫内膜癌患者肿瘤HER2表达。
  • 三分之一未经选择的子宫内膜癌为HER2 2+或3+,可能符合当前NCCN列出的HER2靶向抗体药物偶联物治疗条件。
  • HER2表达分布于所有组织学和分子亚型,作者认为所有子宫内膜肿瘤应行HER2免疫组化检测。

研究设计与样本

  • 回顾性、单机构研究,纳入18个月内因子宫内膜癌接受手术的患者。
  • 共249例新诊断子宫内膜癌患者接受子宫切除术,其中44例为晚期(III/IV期),203例为早期(I/II期)。
  • 220例肿瘤进行了HER2免疫组化检测,对部分2+病例反射进行FISH检测。

主要发现

  • 220例检测肿瘤中,131例(59.5%)HER2表达,67例(30.5%)为2+或3+。
  • HER2表达肿瘤较HER2 0肿瘤更常见于晚期(25.3% vs 10.5%;χ2(1, N=220)=7.40,p=0.0065)。
  • HER2表达肿瘤较HER2 0肿瘤更常见于非子宫内膜样组织学(34.3% vs 14.0;χ2(1, N=220)=11.20,p=0.008)。
  • HER2表达肿瘤较HER2 0肿瘤更常见于p53异常(27.6% vs 12.8%;χ2(2, N=217)=6.7,p=0.035)。

关键数值与推荐

  • HER2免疫组化表达定义为1+、2+或3+。
  • HER2免疫组化2+或3+的肿瘤可能符合当前NCCN列出的HER2靶向抗体药物偶联物治疗条件。

临床怎么用

  • 作者认为所有子宫内膜肿瘤应行HER2免疫组化检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Trastuzumab deruxtecan, a HER2 antibody drug conjugate (ADC), is active in HER2 expressing gynecologic cancers. This study aims to determine the proportion of endometrial cancers (EC) that are HER2 expressing and eligible for these ADCs. METHODS: This was a retrospective, single-institution study of patients who underwent surgery for EC over 18 months. Clinical HER2 testing consisted of HER2 IHC and reflex FISH for select 2+ IHC. The outcome of interest was the proportion of patients with HER2 expressing tumors by IHC (1+, 2+, 3+). Chi-square tests of independence were performed to examine relationships between categorical variables and HER2 expression. RESULTS: Two hundred forty-nine patients with newly diagnosed EC underwent hysterectomy. Forty-four patients were diagnosed at advanced stage (III/IV) and 203 at early stage (I/II). HER2 IHC was performed on 220 tumors. One hundred thirty-one (59.5 %) had HER2 expression by and 67 (30.5 %) were 2+ or 3+. HER2 expressing tumors were more likely to be advanced stage (25.3 % vs 10.5 %; χ2 (1, N = 220) = 7.40, p = 0.0065), non-endometrioid histology (34.3 % vs 14.0, χ2 (1, N = 220) = 11.20, p = 0.008), and p53 aberrant (27.6 % vs 12.8 %, χ2 (2, N = 217) = 6.7, p = 0.035) than HER2 0 tumors. CONCLUSION: In this retrospective study, 60 % of newly diagnosed EC patients were HER2 expressing by IHC. One-third of unselected EC were HER2 2+ or 3+ and would potentially qualify for current NCCN listed HER2 directed ADCs. HER2 expression was distributed across all histologic and molecular EC subtype suggesting that all endometrial tumors should undergo HER2 IHC testing.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hacker KE, A Fleming K, Gupta M, et al. HER2 expression in an endometrial cancer cohort. Gynecol Oncol. 2025. PMID: 40768863. doi:10.1016/j.ygyno.2025.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。